Kinetic analysis of human and canine P-glycoprotein-mediated drug transport in MDR1-MDCK cell model: Approaches to reduce false-negative substrate classification

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3436-3446

  Li, Jibin ^a   Wang, Ying ^a   Hidalgo, Ismael J ^a  

^a Absorption Systems   (United States)

Author keywords

ABC transporters; Drug interactions; Drug transport; in vitro model; Mathematical model; MDCK cells; Membrane transporter; P glycoprotein; Transporters

Indexed keywords

AMPRENAVIR; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL CELL; ARTICLE; CALCULATION; DRUG CLASSIFICATION; DRUG DIFFUSION; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ABC TRANSPORTERS; DRUG INTERACTIONS; DRUG TRANSPORT; IN VITRO MODEL; MATHEMATICAL MODEL; MDCK CELLS; MEMBRANE TRANSPORTER; P-GLYCOPROTEIN; TRANSPORTERS;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; DOGS; GENE EXPRESSION; HUMANS; KINETICS; MADIN DARBY CANINE KIDNEY CELLS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TRANSFECTION;

EID: 84881617338     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23523     Document Type: Article

References (20)

1. Raub TJ. 2006. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 3(1):3-25.
2. Zhou SF. 2008. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38(7-8):802-832.
3. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. 2007. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8):927-941.
4. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Wah Yee S, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
5. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299(2):620-628.
6. Lin JH. 2007. Transporter-mediated drug interactions: Clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3(1):81-92.
7. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. 1988. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85(12):4486-4490.
8. Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19(6):765-772.
9. Kuteykin-Teplyakov K, Luna-Tortos C, Ambroziak K, Loscher W. 2010. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol 160(6):1453-1463.
10. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, Friedberg T. 2002. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64(11):1569-1578.
11. US Department of Health and Human Services, Food and Drug Administration, Center of Drug Evaluation and Research (CDER). 2012. Draft guidance for industry. Drug interaction studies-Study design, data analysis, implications for dosing, and labeling recommendations. Accessed March 4, 2013, at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
12. Kalvass JC, Pollack GM. 2007. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24(2):265-276.
13. Di L, Whitney-Pickett C, Umland JP, Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ 3rd, Davidson RE, Smith R, Reyner EL, Lee C, Feng B, Rotter C, Varma MV, Kempshall S, Fenner K, El-Kattan AF, Liston TE, Troutman MD. 2011. Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci 100(11):4974-4985.
14. Lloyd C, Schevzov G, Gunning P. 1992. Transfection of nonmuscle beta- and gamma-actin genes into myoblasts elicits different feedback regulatory responses from endogenous actin genes. J Cell Biol 117(4):787-797.
15. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. 2008. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36(2):268-275.
16. Guan F, Uboh CE, Soma LR, Birks E, Chen J, You Y, Rudy J, Li X. 2008. Differentiation and identification of recombinant human erythropoietin and darbepoetin alfa in equine plasma by LC-MS/MS for doping control. Anal Chem 80(10):3811-3817.
17. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, Terasaki T. 2008. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25(6):1469-1483.
18. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. 2006. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3(1):55-61.
19. Xia CQ, Liu N, Yang D, Miwa G, Gan LS. 2005. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33(5):637-643.
20. Wang Z, Pal D, Patel A, Kwatra D, Mitra AK. 2013. Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines. Int J Pharm 441(1-2):40-49.